Tangram Therapeutics
R&D
- [email protected]
- Website
- https://tangramtx.com
- Membership category
- Corporate
4 Kingdom Street, Paddington Central, London, W2 6BD, United Kingdom
About Tangram Therapeutics
Tangram Therapeutics is a clinical-stage biotech company uniting computation and RNAi to make differentiated medicines faster. Tangram leverages proprietary network analytics to identify gene targets key to disease biology and is rapidly advancing a pipeline of GalOmic RNAi medicines for diseases with high unmet need.
Tangram’s lead program, TGM-312 for MASH, is currently progressing through a Phase 1/2 study, with initial data anticipated 2H 2026. Preclinically, TGM-312 has demonstrated best-in-disease efficacy across steatosis, inflammation and fibrosis. A second program, TGM-148 for bleeding disorders, is on track for a CTA submission in Q3 2026 and clinical entry by year end. TGM-148 has broad potential across bleeding disorder indications as a safe prophylactic treatment option.
